1
|
Seang S, Itani O, Monsel G, Abdi B, Marcelin AG, Valantin MA, Palich R, Fayçal A, Pourcher V, Katlama C, Tubiana R. Long COVID-19 symptoms: clinical characteristics and recovery rate among non-severe outpatients over a six-month follow-up. Infect Dis Now 2022; 52:165-169. [PMID: 35158095 PMCID: PMC8832844 DOI: 10.1016/j.idnow.2022.02.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 11/08/2021] [Accepted: 02/08/2022] [Indexed: 01/08/2023]
Abstract
Background To describe persistent symptoms in long COVID-19 non-severe outpatients and report the 6-month clinical recovery (CR) rate. Methods Observational study enrolling outpatients (≥ 18 years) with confirmed non-severe COVID-19 (positive nasopharyngeal RT-PCR or presence of SARS-CoV-2 antibodies) who consulted for persistent symptoms after the first pandemic wave (March-May 2020). CR was assessed at the 6-month visit and defined as complete (no symptom), partial (persistent symptoms of lower intensity) or lack of recovery (no improvement). Results Sixty-three patients (79% women, mean age: 48 years) enrolled; main symptoms (mean 81 days after acute infection): asthenia/myalgia (77%), dyspnea (51%), headaches (35%), cough (33%). At 6 months (n = 56), 30% had complete, 57% partial, and 13% lack of recovery. The proportion of patients with > 2 persistent symptoms was 26% at 6 months (main symptoms: dyspnea [54%] and asthenia/myalgia [46%]). Conclusion We observed a slow but high recovery rate at 6 months among these outpatients.
Collapse
Affiliation(s)
- S Seang
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France.
| | - O Itani
- AP-HP, Infectious Diseases department, Pitié-Salpêtrière hospital, Paris, France
| | - G Monsel
- AP-HP, Infectious Diseases department, Pitié-Salpêtrière hospital, Paris, France
| | - B Abdi
- Sorbonne University, Virology department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - A-G Marcelin
- Sorbonne University, Virology department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - M-A Valantin
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - R Palich
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - A Fayçal
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - V Pourcher
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - C Katlama
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| | - R Tubiana
- Sorbonne University, Infectious Diseases department, Pitié-Salpêtrière hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
| |
Collapse
|
2
|
Palich R, Wirden M, Peytavin G, Lê MP, Seang S, Abdi B, Schneider L, Tubiana R, Valantin MA, Paccoud O, Soulié C, Calvez V, Katlama C, Marcelin AG. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations. J Antimicrob Chemother 2021; 75:2981-2985. [PMID: 32642769 DOI: 10.1093/jac/dkaa273] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 05/15/2020] [Accepted: 05/24/2020] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVES To assess genotypic sensitivity scores (GSSs), plasma antiretroviral concentrations (PACs) and immunovirological outcomes at Week 96 (W96) in patients with persistent low-level viraemia (LLV). METHODS On 1 January 2017, we analysed data from patients on three-drug regimens with persistent LLV defined as at least two consecutive plasma viral loads (pVLs) between 21 and 200 copies/mL (including one pVL of ≥50 copies/mL), at the Pitié-Salpêtrière Hospital. Outcomes were: GSS, PACs and HIV-DNA load at study entry; and virological status and proportion of patients with resistance-associated mutations (RAMs) at W96. RESULTS Fifty-seven patients were included, with median age of 52.6 years (IQR 45.2-57.9), last CD4 count of 658 cells/mm3 (IQR 462-909) and total ART duration of 10.2 years (IQR 5.7-15.2). LLV duration was 14.0 months (IQR 5.5-22.3). GSS was 3 in 46/57 (81%) patients and PACs were adequate in 53/57 (93%) patients. Median total HIV-DNA was 2.65 log10 copies/106 cells (IQR 2.44-2.86). During follow-up, 26/57 (46%) had experienced ART modifications. At W96, 38/57 (67%) patients remained with LLV, 15/60 (26%) had achieved confirmed pVL of <20 copies/mL and 4/57 (7%) had virological failure. The four virological failures were due to three ART interruptions and one incomplete adherence (selection of Y181C RAM). No factors (patient characteristics at study entry, GSS, PACs, total HIV-DNA load and ART modification) were associated with W96 viral outcome, except for time from HIV diagnosis and the LLV duration at study entry. CONCLUSIONS A substantial number of patients harbouring LLV had no resistance to ART and adequate PACs. Two-thirds of these patients remained with this LLV status.
Collapse
Affiliation(s)
- R Palich
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - M Wirden
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Virology, F-75013 Paris, France
| | - G Peytavin
- Bichat University Hospital, AP-HP, Pharmacology and Toxicology Department, IAME, INSERM 1137, Paris, France
| | - M-P Lê
- Bichat University Hospital, AP-HP, Pharmacology and Toxicology Department, IAME, INSERM 1137, Paris, France
| | - S Seang
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - B Abdi
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Virology, F-75013 Paris, France
| | - L Schneider
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - R Tubiana
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - M-A Valantin
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - O Paccoud
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - C Soulié
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Virology, F-75013 Paris, France
| | - V Calvez
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Virology, F-75013 Paris, France
| | - C Katlama
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases, F-75013 Paris, France
| | - A-G Marcelin
- Sorbonne Université, INSERM, Pierre Louis Epidemiology and Public Health Institute (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Virology, F-75013 Paris, France
| |
Collapse
|
3
|
Cousyn L, Sellem B, Palich R, Bendetowicz D, Agher R, Delorme C, Tubiana R, Valantin MA, Seang S, Schneider L, Fayçal A, Dudoit Y, Abdi B, Ndoadoumgue A, Assoumou L, Katlama C. Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study. Infect Dis Now 2021; 51:440-444. [PMID: 33766735 PMCID: PMC7983360 DOI: 10.1016/j.idnow.2021.03.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 03/04/2021] [Accepted: 03/15/2021] [Indexed: 01/05/2023]
Abstract
OBJECTIVES To describe the characteristics, evolution and risk factors for long-term persistence of olfactory and gustatory dysfunctions (OGD) in COVID-19 outpatients. PATIENTS AND METHODS We conducted a prospective study in SARS-CoV-2 infected outpatients with OGD. Weekly phone interviews were set up starting from COVID-19 onset symptoms and over the course of 60 days, using standardized questionnaires that included a detailed description of general symptoms and OGD. The primary outcome was the proportion of patients with complete recovery of OGD at D30. Rate and time to recovery of OGD, as well as risk factors for late recovery (>30 days), were evaluated using Cox regression models. RESULTS Ninety-eight outpatients were included. The median time to onset of OGD after first COVID-19 symptoms was 2 days (IQR 0-4). The 30-day recovery rate from OGD was 67.5% (95% CI 57.1-75.4) and the estimated median time of OGD recovery was 20 days (95% CI 13-26). Risk factors for late recovery of OGD were a complete loss of smell or taste at diagnosis (HR=0.26, 95% CI 0.12-0.56, P=0.0005) and age over 40 years (HR=0.56, 95% CI 0.36-0.89, P=0.01). CONCLUSIONS COVID-19 patients with complete loss of smell or taste and over age 40 are more likely to develop persistent OGD and should rapidly receive sensorial rehabilitation.
Collapse
Affiliation(s)
- L Cousyn
- Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Paris Brain Institute (Inserm, CNRS, Sorbonne Université), Paris, France.
| | - B Sellem
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - R Palich
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - D Bendetowicz
- Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Paris Brain Institute (Inserm, CNRS, Sorbonne Université), Paris, France
| | - R Agher
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - C Delorme
- Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - R Tubiana
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - M-A Valantin
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - S Seang
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - L Schneider
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - A Fayçal
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Y Dudoit
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - B Abdi
- Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France; Department of Virology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - A Ndoadoumgue
- Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - L Assoumou
- Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - C Katlama
- Department of Infectious Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Inserm, Sorbonne Université, Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | | |
Collapse
|
4
|
Seang S, Ktorza N, Monsel G, Abdi B, Marcelin A, Valantin M, Pourcher V, Caumes E, Katlama C, Tubiana R. Description clinique et diagnostique sérologique des patients présentant des symptômes persistants après suspicion d’infection à SARS-COV-2. Med Mal Infect 2020. [PMCID: PMC7442070 DOI: 10.1016/j.medmal.2020.06.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Galloway M, Hunter E, Akoulitchev A, Vigneswaran S, Abdi B, Denton C, Abraham D, Stratton R. OP0254 CHROMATIN CONFORMATION SIGNATURE ANALYSIS IN EARLY VS LATE SCLERODERMA PHENOTYPES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease in which clinical outcomes vary widely. Predicting outcomes on an individual basis remains challenging despite progress made through autoantibody analysis and gene expression profiling. Effective targeted therapies are evolving and accurately predicting outcomes is important to enable patient stratification for therapy.Chromatin Conformation Signature (CCS) profiling of peripheral blood for systemic epigenetic deregulations could be used for such a purpose. The EpiSwitch platform offering high throughput and resolution chromosome conformation (3C) capture detects significant regulatory changes in 3D genome architecture and maps long range interaction between distant genomic locations. This then reveals the spatial disposition and physical properties of the chromosome, such as chromatin loops and inter-chromosomal connections, which have a role in network organization and genetic epistasis controlling gene expression. EpiSwitch automated platform has been successfully utilised in patient stratification in RA, MS and other indications.This methodology could be applied to patients with SSc to identify CCS associated with different phenotypes and may ultimately be used to stratify and identify patients into pathogenic subtypes.Objectives:We aimed to determine significant CCSs associated with early and late phenotypes of SSc.Methods:The EpiSwitch-based chromosome conformation capture (3C) method was applied to blood samples from early phenotype, and late phenotype SSc patients. Intact nuclei were isolated from peripheral blood mononuclear cells and subjected to formaldehyde fixation resulting in crosslinking between physically touching segments of the genome via contacts between their DNA bound proteins. For quantification of cross-linking frequencies, the cross linked DNA was digested and then subjected to ligation. Cross-linking was then reversed and individual ligation products detected and quantified by EpiSwitch custom oligo array annotated across the whole genome to the anchoring sites of 3D genome architecture.Results:7 significant CCSs were found over the HLA-C, HLA-B and TNF regions on Chromosome 6 in the early phenotype. The top 8 pathways for genetic locations associated to the CCSs are shown in Table 1.Table 1.Top 8 pathways for genetic locations associated to significant CCS for the early phenotype.GeneSet1Natural Killer cell mediated cytotoxicity2Immunoregulatory interations between a lymphoid cell and a non-lymphoid cell3Antigen Processing & presentation4Phagosome5Graft versus host disease6Type 1 diabetes mellitus7Osteoclast differentiation8Class 1 MHC mediated antigen processing & presentation2 significant CCSs were found centred around the IFNG region of chromosome 12 in the late phenotype. The top 8 pathways for genetic locations associated to significant CCSs are shown in Table 2.Table 2.Top 8 pathways for genetic locations associated to significant CCS for the late phenotype.GeneSet1Surfactant metabolism2IL12 signalling mediated by STAT43Protein digestion & absorption4Calcineruin regulated NFAT dependent transcription in lymphocytes5Transcriptional misregulation in cancer6Kaposi’s sarcoma associated herpes virus infection7IL2 mediated signalling events8Inflammatory bowel diseaseConclusion:Significant CCSs, as part of 3D genomic regulatory control, and their associated pathways for the genetic locations, were identified in both late and early phenotypes. There were distinct CCSs in the early phenotype compared to the late suggesting the CCSs change as the disease progresses and varies between phenotypes. If CCSs could be linked to each clinically defined subgroup across a SSc cohort they could be used as a biomarker tool to predict outcome and progression in patients.Disclosure of Interests:Megan Galloway: None declared, Ewan Hunter: None declared, Alexandre Akoulitchev: None declared, Shivanee Vigneswaran: None declared, Bahja Abdi: None declared, Christopher Denton Grant/research support from: GlaxoSmithKline, Inventiva, CSF Behring, Consultant of: Roche-Genentech, Actelion, GlaxoSmithKline, Sanofi Aventis, Inventiva, CSL Behring, Boehringer Ingelheim, Bayer, David Abraham: None declared, Richard Stratton: None declared
Collapse
|
6
|
Sassi M, Dibej W, Abdi B, Abderrazak F, Hassine M, Babba H. [Diagnostic performance of graphical anomalies in the detection of large platelets and platelet clumps]. ACTA ACUST UNITED AC 2016; 63:248-51. [PMID: 26524955 DOI: 10.1016/j.patbio.2015.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Accepted: 09/29/2015] [Indexed: 10/22/2022]
Abstract
UNLABELLED Thrombocytopenia is a current situation for making a blood smear in routine practice in a medical analysis laboratory. Recent automated hematology analyzers enumerate platelets and generate histograms and specific flags. Operators must be aware of the characteristics of their analyzer in order to avoid spurious results in the case where microscopy review is not possible. OBJECTIVE We evaluated the diagnostic performance of various graphical anomalies in the detection of large platelets and platelet clumps. PATIENTS AND METHODS Three hundred cases of thrombocytopenia were included in the study on the basis of a platelet count less than 150 × 10(9)/L. This evaluation is expressed by the results of the sensitivity, specificity, positive predictive value and negative predictive value compared to the microscopic review of blood smear. RESULTS Graphical performances are variable according to microscopic review of blood smears. Indeed, a not fitted curve is the most sensitive change on platelet histogram to the presence of large platelet. A high specificity to the presence of platelet clumps is announced when the platelet curve fails to return to the baseline. Moreover, characteristic findings on the DIFF scattergram are very specific to the presence of platelet clumps. CONCLUSION A normal platelet histogram can validate with great confidence thrombocytopenia in cases where a blood smear cannot be read immediately.
Collapse
Affiliation(s)
- M Sassi
- Laboratoire du centre de maternité et de néonatologie de Monastir, 5000 Monastir, Tunisie; Faculté de pharmacie, université de Monastir, 5000 Monastir, Tunisie.
| | - W Dibej
- Laboratoire du centre de maternité et de néonatologie de Monastir, 5000 Monastir, Tunisie; Faculté de pharmacie, université de Monastir, 5000 Monastir, Tunisie
| | - B Abdi
- Laboratoire du centre de maternité et de néonatologie de Monastir, 5000 Monastir, Tunisie; Faculté de pharmacie, université de Monastir, 5000 Monastir, Tunisie
| | - F Abderrazak
- Faculté de pharmacie, université de Monastir, 5000 Monastir, Tunisie; Laboratoire d'hématologie et banque du sang, hôpital Fattouma Bourguiba, 5000, Monastir, Tunisie
| | - M Hassine
- Faculté de pharmacie, université de Monastir, 5000 Monastir, Tunisie; Laboratoire d'hématologie et banque du sang, hôpital Fattouma Bourguiba, 5000, Monastir, Tunisie
| | - H Babba
- Laboratoire du centre de maternité et de néonatologie de Monastir, 5000 Monastir, Tunisie; Faculté de pharmacie, université de Monastir, 5000 Monastir, Tunisie
| |
Collapse
|
7
|
|
8
|
|